ResearcherEli Lilly (United Kingdom)No recent work listed
Ivelina Gueorguieva
Matched on ORCID iD 0000-0001-5864-8924; OpenAlex author ID A5020397401. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers
Papers 4
- Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Co-author DOI 10.1136/jitc-2020-002068↗
- Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
- Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cance… Co-author DOI 10.1007/s00280-019-03931-1↗
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Co-author DOI 10.1038/s41416-018-0246-z↗
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Teresa Mercade Macarulla · 4 shared papers, 2018–2021 · strength 0.37
- Paper Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pan… DOI 10.1200/jco.20.02232↗
- Paper Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in met… DOI 10.1136/jitc-2020-002068↗
- Paper Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galuni… DOI 10.1007/s00280-019-03931-1↗
- Karim Adnane Benhadji · 3 shared papers, 2018–2021 · strength 0.26
- Paper Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in met… DOI 10.1136/jitc-2020-002068↗
- Paper Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galuni… DOI 10.1007/s00280-019-03931-1↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Davide Melisi · 3 shared papers, 2018–2021 · strength 0.26
- Paper Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in met… DOI 10.1136/jitc-2020-002068↗
- Paper Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galuni… DOI 10.1007/s00280-019-03931-1↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Valeria Merz · 2 shared papers, 2019–2021 · strength 0.20
- Paper Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in met… DOI 10.1136/jitc-2020-002068↗
- Paper Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galuni… DOI 10.1007/s00280-019-03931-1↗
- Rocio García‐Carbonero · 2 shared papers, 2018–2021 · strength 0.17
- Paper Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in met… DOI 10.1136/jitc-2020-002068↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Josep M. Tabernero · 2 shared papers, 2018–2019 · strength 0.16
- Paper Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galuni… DOI 10.1007/s00280-019-03931-1↗
- Paper Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. DOI 10.1038/s41416-018-0246-z↗
- Andrés Jesús Muñoz Martín · 1 shared paper, 2021 · strength 0.11
- Sara Lonardi · 1 shared paper, 2021 · strength 0.11
- Joel Randolph Hecht · 1 shared paper, 2021 · strength 0.11
- Baek‐Yeol Ryoo · 1 shared paper, 2021 · strength 0.11
- Joon Oh Park · 1 shared paper, 2021 · strength 0.11
- Johanna C. Bendell · 1 shared paper, 2021 · strength 0.11
- Richard Greil · 1 shared paper, 2021 · strength 0.11
- Charles D. Lopez · 1 shared paper, 2021 · strength 0.11
- Eric Van Cutsem · 1 shared paper, 2021 · strength 0.11
- Anna M. Varghese · 1 shared paper, 2021 · strength 0.10
- Do‐Youn Oh · 1 shared paper, 2021 · strength 0.10
- Antoine Hollebecque · 1 shared paper, 2021 · strength 0.10
- Emiliano Calvo · 1 shared paper, 2021 · strength 0.10
- Erkut Hasan Borazanci · 1 shared paper, 2021 · strength 0.10
- G. Deplanque · 1 shared paper, 2018 · strength 0.07
- Denis Pezet · 1 shared paper, 2018 · strength 0.07
- Helmut Oettle · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.